Harvest Technology accelerates defence strategy focus
Harvest Technology Group (ASX:HTG) prioritises its defence-focused strategy and Nodestream platform acceleration following an independent review.

Crypto journalist for Grafa, with nearly 10 years of experience covering blockchain, Web3, and NFT gaming trends. MBA & Economics grad.
Harvest Technology Group (ASX:HTG) prioritises its defence-focused strategy and Nodestream platform acceleration following an independent review.
IMDEX (ASX:IMD) has formalised its global expansion strategy by acquiring the remaining 60% interest in Krux Analytics.
The Federal Court is set to slap Electro Optic Systems (ASX:EOS) with a $4 million penalty following a breach of its disclosure obligations.
The Federal Government warns of a looming winter energy crisis as Resources Minister Madeleine King issues a formal notice to potentially invoke the "gas trigger."
Pathkey.AI (ASX:PKY) has executed a strategic services agreement with Imunexus Therapeutics.
Novo Nordisk (NYSE:NVO) has intensified its rivalry with Eli Lilly (NYSE:LLY), releasing a provocative cross-trial analysis that claims its experimental Wegovy pill is both more effective and better tolerated than Lilly’s recently approved obesity tablet, Foundayo.
ECARX Holdings (NASDAQ:ECX) achieved a historic financial turning point in the final months of 2025, reporting its first-ever quarterly net income as a public company alongside a surge in shipments for its flagship automotive computing platforms.
Adagene (NASDAQ:ADAG) and Incyte (NASDAQ:INCY) have entered into a clinical trial collaboration to evaluate a potent combination of immunotherapy agents in patients with microsatellite stable colorectal cancer (MSS CRC), a disease state notoriously resistant to standard immune checkpoint inhibitors.
AirSculpt Technologies (NASDAQ:AIRS), a national provider of body contouring procedures, reported its fourth-quarter and full-year fiscal 2025 financial results.
Priovant Therapeutics, a majority-owned subsidiary of Roivant Sciences (NASDAQ:ROIV), provided a significant update on its late-stage immunology pipeline on Thursday, April 2, 2026.